Biodesix Q3 2024 revenue up 35% to $18.2M; lung diagnostic revenue grows 40% YoY

BIODESIX INC

2024-Q3 EPS reported -$0.28 revenue$50,894,000

Total revenue $18.2M (+35% YoY); lung diagnostic revenue $17.2M (+40% YoY).
Net loss improved 6% to $10.3M; Adjusted EBITDA loss $5.6M.
Gross profit margin 77.0% vs 76.1% in Q3 2023; test volume 13,900 (+34% YoY).
Reiterated FY 2024 revenue guidance $70M-$72M; targeting Adjusted EBITDA profitability H2 2025.
Presented Nodify XL2/CDT data at CHEST; launched CLARIFY study for diverse patient data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.